Spatiotemporal Evolution of Malignant Hepatocyte Clones Unveils Immune Evasion Features and Therapeutic Vulnerabilities in Hepatocellular Carcinoma
Biotechnology Journal · 2026
DOI: 10.1002/biot.70181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2026. Verfasst von Shizheng Xiong und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM), School of Chemistry and Life Sciences, Nanjing Universit…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Hepatocytes, Immune Evasion. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the key project of Social Development in Jiangsu Province, the key projects of Natural Science Research in Universities of Jiangsu Province.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC), a highly lethal disease often developing in the context of chronic liver disease, is marked by high relapse rates and low 5‐year survival. To investigate the multicellular ecosystem and molecular features of hepatocarcinogenesis and progression, a comprehensive analysis integrating single‐cell and spatial transcriptomics was conducted. Significant alterations were observed in various cell types, notably an increase in liver parenchymal and endothelial cells, which play critical roles in tissue repair and angiogenesis. Scissor + cells, predominantly hepatocytes, were identified as potentially evolving into malignant cells with poor prognosis and enhanced immune evasion capabilities. Key genes associated with Scissor + cells exhibited potential as cancer prognostic markers. Additionally, the disruption of cellular communication networks during malignant progression revealed the evolution of hepatocytes into cancerous phenotypes. The enhanced signaling pathways, such as MDK‐SDC4 and COL4A‐SDC, were identified as pivotal in driving the malignant transformation of hepatocytes. This transformative process, wherein Scissor + cells acquire malignant features, highlights novel mechanisms of cancer progression. These findings provide deeper insights into hepatocarcinogenesis and offer potential avenues for targeted and personalized therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM), School of Chemistry and Life Sciences, Nanjing University of Posts & Telecommunications, Nanjing, China.
- School of Life Science, Nanjing Normal University, Nanjing, China.
Förderung
- National Natural Science Foundation of China
- the key project of Social Development in Jiangsu Province
- the key projects of Natural Science Research in Universities of Jiangsu Province
- Qinglan Project in Jiangsu Province
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
- Priority Academic Program Development of Jiangsu Higher Education Institution (PAPD)
Zitieren
APA
Xiong, S., Ren, D., Jin, J., Zhao, L., Gong, C., Liu, J., Zheng, W., He, Z., Guo, H., Guo, L., & Liang, T. (2026). Spatiotemporal Evolution of Malignant Hepatocyte Clones Unveils Immune Evasion Features and Therapeutic Vulnerabilities in Hepatocellular Carcinoma. Biotechnology Journal. https://doi.org/10.1002/biot.70181
Vancouver
Xiong S, Ren D, Jin J, Zhao L, Gong C, Liu J, et al. Spatiotemporal Evolution of Malignant Hepatocyte Clones Unveils Immune Evasion Features and Therapeutic Vulnerabilities in Hepatocellular Carcinoma. Biotechnology Journal. 2026. doi:10.1002/biot.70181
BibTeX
@article{Xiong2026,
author = {Xiong, Shizheng and Ren, Dekang and Jin, Jiaming and Zhao, Linjie and Gong, Chengjun and Liu, Jiarui and Zheng, Wanjie and He, Zhiheng and Guo, Haochuan and Guo, Li and Liang, Tingming},
title = {Spatiotemporal Evolution of Malignant Hepatocyte Clones Unveils Immune Evasion Features and Therapeutic Vulnerabilities in Hepatocellular Carcinoma},
journal = {Biotechnology Journal},
year = {2026},
doi = {10.1002/biot.70181}
}
EUVIMED